Contraceptive Provision to Women With Intellectual and Developmental Disabilities Enrolled in Medicaid

Obstet Gynecol. 2023 Dec 1;142(6):1477-1485. doi: 10.1097/AOG.0000000000005421. Epub 2023 Oct 26.

Abstract

Objective: To compare contraceptive provision to women with and without intellectual and developmental disabilities enrolled in North Carolina Medicaid.

Methods: Our retrospective cohort study used 2019 North Carolina Medicaid claims to identify women aged 15-44 years with and without intellectual and developmental disabilities at risk for pregnancy who were continuously enrolled during 2019 or had Family Planning Medicaid with at least one claim. We calculated the proportion in each cohort who received 1) most or moderately effective contraception, 2) long-acting reversible contraception, 3) short-acting contraception, and 4) individual methods. We classified contraceptive receipt by procedure type and disaggregated across sociodemographic characteristics. Adjusting for age, race, ethnicity, and urban or rural setting, we constructed logistic regression models to estimate most or moderately effective contraceptive provision odds by intellectual and developmental disability status and by level or type of intellectual and developmental disability. We performed subanalyses to estimate co-occurrence of provision and menstrual disorders.

Results: Among 9,508 women with intellectual and developmental disabilities and 299,978 without, a significantly smaller proportion with intellectual and developmental disabilities received most or moderately effective contraception (30.1% vs 36.3%, P <.001). With the exception of injectable contraception, this trend was consistent across all measures and remained statistically significant after controlling for race, ethnicity, age, and urban or rural status (adjusted odds ratio 0.75, 95% CI 0.72-0.79; P <.001). Among those who received most or moderately effective contraception, a significantly greater proportion of women with intellectual and developmental disabilities had co-occurring menstrual disorders (31.3% vs 24.3%, P <.001).

Conclusion: These findings suggest disparities in contraceptive provision and potential differences in clinical indication by intellectual and developmental disability status. Future studies should investigate reasons for and barriers to contraceptive use among women with intellectual and developmental disabilities.

MeSH terms

  • Child
  • Contraception / methods
  • Contraceptive Agents*
  • Developmental Disabilities
  • Female
  • Humans
  • Medicaid*
  • Pregnancy
  • Retrospective Studies
  • United States

Substances

  • Contraceptive Agents